AI Article Synopsis
- Beta-synuclein is identified as a potential biomarker for detecting synaptic damage, particularly in conditions like sporadic Creutzfeldt-Jakob disease.
- In a study comparing 150 cases of sporadic Creutzfeldt-Jakob disease to 106 cases of other rapidly progressive dementias, beta-synuclein showed superior diagnostic accuracy in cerebrospinal fluid and blood.
- Its performance in cerebrospinal fluid (AUC 0.95) and plasma (AUC 0.91) was better than other biomarkers like protein 14-3-3 and total tau, suggesting beta-synuclein could be a breakthrough in diagnosing this disease.
Article Abstract
Beta-synuclein is a promising cerebrospinal fluid and blood biomarker of synaptic damage. Here we analysed its accuracy in the discrimination between sporadic Creutzfeldt-Jakob disease (n = 150) and non-prion rapidly progressive dementias (n = 106). In cerebrospinal fluid, beta-synuclein performed better than protein 14-3-3 (AUC 0.95 vs. 0.89) and, to a lesser extent, than total tau (AUC 0.92). Further, the diagnostic value of plasma beta-synuclein (AUC 0.91) outperformed that of plasma tau (AUC 0.79) and neurofilament light chain protein (AUC 0.65) and was comparable to that of cerebrospinal fluid biomarkers. Beta-synuclein might represent the first highly accurate blood biomarker for the diagnosis of sporadic Creutzfeldt-Jakob disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578883 | PMC |
| http://dx.doi.org/10.1002/acn3.51873 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!